TY - ADVS
T1 - Leuprolide Acetate for Prostate Cancer: Achieving Effective Testosterone Suppression
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Tuesday, June 8, 2021 Androgen-deprivation therapy is the standard of care for prostate cancer. However, the dosing schedules used to suppress testosterone to delay disease progression and improve survival are essential, emphasizing the duration of action. A recent report based on an analysis of U.S.
PY - 2021/6/8
Y1 - 2021/6/8
N2 - Androgen-deprivation therapy is the standard of care for prostate cancer. However, the dosing schedules used to suppress testosterone to delay disease progression and improve survival are essential, emphasizing the duration of action. A recent report based on an analysis of U.S. clinical data, conducted by E. David Crawford, MD, and colleagues from the University of California San Diego, La Jolla, was published in The Journal of Urology.
AB - Androgen-deprivation therapy is the standard of care for prostate cancer. However, the dosing schedules used to suppress testosterone to delay disease progression and improve survival are essential, emphasizing the duration of action. A recent report based on an analysis of U.S. clinical data, conducted by E. David Crawford, MD, and colleagues from the University of California San Diego, La Jolla, was published in The Journal of Urology.
UR - https://jnccn360.org/prostate/medical-literature/leuprolide-acetate-for-prostate-cancer-achieving-effective-testosterone-suppression/
M3 - Web publication/site
ER -